ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009
given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic
parameters for ABI-009 when given on a weekly schedule.